Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Merck & Co Inc Reaffirms FY 2013 EPS Guidance; Lowers FY 2013 Revenue Guidance


Tuesday, 30 Jul 2013 07:01am EDT 

Merck & Co Inc reiterated that it expects fiscal 2013 non-GAAP EPS to be between $3.45 and $3.55, and revised 2013 GAAP EPS to be between $1.84 and $2.05. The 2013 non-GAAP range excludes acquisition-related costs, costs related to restructuring programs and certain other items. At current exchange rates, Merck now expects fiscal 2013 sales to be approximately 5% to 6% below prior year levels with foreign exchange accounting for approximately 3 percentage points of the decline. The Company reported revenue of $47.267 billion in fiscal 2012. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report EPS of $3.48 and revenue of $45.025 billion for fiscal 2013. 

Company Quote

59.17
0.32 +0.54%
22 Aug 2014